evolocumab
amgen
['evolocumab', 'cardio']
legacy effect of pcsk9 inhibition. "long-term ldl-c lowering with evolocumab was associated with persistently low rates of adverse events for over &gt;8 years" #esccongress #cardiotwitter 
Associate Professor, Faculty of Medicine @universitelaval Cardiometabolic diseases prevention and genetics researcher @IUCPQ Chroniqueur @rcmoteur EN/FR